Bulletin from Bactiguard Holding AB’s (publ) Annual General Meeting
At Bactiguard Holding AB’s (publ) Annual General Meeting (AGM) on 28 April, 2020, the following resolutions were made:
The AGM adopted the income statements and balance sheets for 2019 and decided that no dividend for the financial year 2019 will be paid. Share premium reserve, retained earnings and the company's loss for the year will be carried forward.
The Board of Directors and CEO were discharged from liability for the financial year 2019.
An annual remuneration of SEK 2 000 000 will be paid to the chairman of the Board and SEK 200 000 to each of the other external directors. No additional remuneration shall be paid for committee work, except for the chairman of the audit committee who will receive a remuneration of SEK 100 000.
The AGM decided on re-election of Jan Ståhlberg, Christian Kinch, Anna Martling and Thomas von Koch and Cecilia Edström was elected new ordinary board member. Christian Kinch was elected as Chairman of the Board.
Deloitte AB was re-elected of the AGM as auditors and that remuneration to the auditors shall be paid according to approved invoices.
The AGM adopted the proposed guidelines for compensation to senior management.
The Annual General Meeting also resolved, with the required majority and in accordance with the Board's proposal, on a new issue of shares by way of set-off as a result of the acquisition of Vigilenz, which means that part of the purchase price for Vigilenz, SEK 19,320,960 will be paid through payment with 241,512 newly issued B shares in Bactiguard Holding AB.
The Board's proposal for authorization for the Board to decide on a new issue of shares, warrants and / or convertibles, with or without deviation from the shareholders' preferential rights, was also approved by the required majority.
Finally, the AGM resolved on updated instructions for the nomination committee in accordance with the nomination committee's proposal.
For further information, please contact:
Cecilia Edström, CEO, phone: +46 8 440 58 80
About Bactiguard
Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission, we develop and supply infection prevention solutions which reduce the risk of healthcare associated infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large.
The Bactiguard technology prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Through our licence partner BD, urinary catheters with Bactiguard’s coating are market leading in the USA and Japan. Bactiguard’s own product portfolio of urinary catheters, endotracheal tubes and central venous catheters prevent some of the most common infections, which appear in the urinary tract, the blood stream and the respiratory tract.
Bactiguard is in a strong expansion phase in the European markets, China, India and the Middle East as well by establishing license agreements in new therapeutic areas. Recently, Bactiguard completed the acquisition of Malaysian Vigilenz, a manufacturer and supplier of medical devices and consumables, primarily within wound care and infection prevention.
Following the acquisition, Bactiguard has about 180 employees around the world. Its headquarters and one of three production facilities are located in Stockholm, the other two in Malaysia.
Bactiguard is listed on Nasdaq Stockholm.
Read more about how Bactiguard saves lives at www.bactiguard.com
Tags: